Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and Commercialize Multiple Accurins



  BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and
  Commercialize Multiple Accurins

BIND Eligible to Receive Approximately $50 Million in Upfront and Development
    Milestone Payments Plus Additional Regulatory and Sales Milestones and
                          Royalties for Each Accurin

Business Wire

CAMBRIDGE, Mass. -- April 03, 2013

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new
class of highly selective targeted and programmable therapeutics called
Accurins^TM, announced today that it has entered into a global collaboration
agreement with Pfizer Inc. to develop and commercialize Accurins utilizing
select small molecule targeted therapies. The collaboration aims to employ
BIND’s Medicinal Nanoengineering® platform to impart tissue and cellular
targeting capabilities to molecularly targeted drugs.

Under the terms of the agreement, Pfizer will have the exclusive option to
pursue development and commercialization of the Accurins selected by its team.
Both companies will work together on preclinical research, and if Pfizer
exercises its option, Pfizer will have responsibility for development and
commercialization of the selected Accurins. BIND could receive up-front and
development milestone payments totaling approximately $50 million and
approximately $160 million in regulatory and sales milestone payments for each
Accurin commercialized as well as tiered royalties on potential future sales.

“Pfizer, a global leader in the development of innovative, molecularly
targeted therapies is an outstanding partner and this agreement demonstrates
the potential of our platform to create targeted Accurins with optimized
therapeutic properties,” said Scott Minick, President and CEO of BIND. “This
is our second collaboration focused on developing novel Accurins based on
BIND’s platform for targeted and programmable therapeutics and further
validates the importance of targeted nanomedicines as a strategic technology
for the pharmaceutical industry.”

"Pfizer has a strong legacy in targeted small molecule drug discovery and
development and continues to be on the cutting edge of innovation in this
area," said Rod MacKenzie, Senior Vice President and Head of
PharmaTherapeutics R&D at Pfizer. "We look forward to working with the team at
BIND Therapeutics to create targeted Accurins with the aim of optimizing the
therapeutic potential of future small molecules."

About Accurins™

BIND Therapeutics is discovering and developing Accurins, proprietary new
best-in-class therapeutics with superior target selectivity and the potential
to improve patient outcomes in the areas of oncology, inflammatory diseases
and cardiovascular disorders. Leveraging its proprietary Medicinal
Nanoengineering® platform, BIND develops Accurins that outperform conventional
drugs by selectively accumulating in diseased tissues and cells. The result is
higher drug concentrations at the site of action with minimal off-target
exposure, leading to markedly better efficacy and safety.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage biopharmaceutical company developing a
new class of highly selective targeted and programmable therapeutics called
Accurins. BIND’s Medicinal Nanoengineering® platform enables the design,
engineering and manufacturing of Accurins with unprecedented control over drug
properties to maximize trafficking to disease sites, dramatically enhancing
efficacy while minimizing toxicities.

BIND is developing a pipeline of novel Accurins that hold extraordinary
potential to become best-in-class drugs and improve patient outcomes in the
areas of oncology, inflammatory diseases and cardiovascular disorders. BIND's
lead product candidate, BIND-014, is currently entering Phase 2 clinical
testing in cancer patients and is designed to selectively target a surface
protein upregulated in a broad range of solid tumors. BIND also develops
Accurins in collaboration with pharmaceutical and biotechnology partners to
enable promising pipeline candidates to achieve their full potential and to
utilize selective targeting to transform the performance of important existing
drug products.

BIND is backed by leading investors Polaris Venture Partners, Flagship
Ventures, ARCH Venture Partners, NanoDimension, DHK Investments,
EndeavourVision and Rusnano. BIND was founded on proprietary technology from
the laboratories of two leaders in the field of nanomedicine, Professors
Robert Langer, David H. Koch Institute Professor of the Massachusetts
Institute of Technology (MIT) and Omid Farokhzad, Associate Professor of
Harvard Medical School. For more information, please visit the company's web
site at www.bindtherapeutics.com.

Contact:

The Yates Network
Kathryn Morris, 845-635-9828
Kathryn@theyatesnetwork.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement